Dynamic Cell Therapies Logo
Dynamic Cell Therapies Welcomes Mahmoud Mahmoudian, PhD, FRS as Chief Business Officer
May 16, 2022
Dynamic Cell Therapies (DCT), welcomes Mahmoud Mahmoudian, PhD, FRS as Chief Business Officer. He is Managing Director and a member of the Investment Committee of Cobro Ventures.  Dr. Mahmoudian brings more than 30 years of global R&D, venture capital, and business development expertise to drive growth strategies and identify novel medicines for development.

“Dr. Mahmoudian brings talent and extensive experience to Dynamic Cell Therapies, as we look for strategic opportunities to partner and further develop our unique technology,” stated Fred Mermelstein, PhD, President and CEO of DCT. “Dr. Mahmoudian combines exceptional venture investment expertise and a deep knowledge of cancer immunotherapies. He will be incredibly valuable to our company, and we are excited to have him join our team.”

Previously, Dr. Mahmoudian was Senior Vice President, Head of Global Oncology External Innovation Hub at Sumitomo, Vice President, Head of Innovative Medicines at Ferring, Chief Innovation Officer and Chair of Executive Committee for Growth at Rohm & Haas (acquired by Dow) and Chief Biotechnology Officer at Eastman. At Merck and GlaxoSmithKline, he led global drug development teams with eight FDA approvals and launches ($15B sales).

Dr. Mahmoudian earned his Doctor and Master of Science in biotechnology from the Imperial College of Science, Technology and Medicine in London, UK. He serves as Executive in Residence at Columbia University and Princeton University, a Fellow of the Royal Society, member of Board of Directors of BioEclipse Therapeutics, Chief Business Officer at AI Proteins, and President & Interim Chief Executive Officer at Mana Therapeutics.